Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 8/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15437775 | 0.83 | KMT2A (0.50) | LCKMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL6310937 | 0.78 | LCK (0.57) | LCKL3MBTL1 | |
| SCHEMBL15437985 | 0.78 | CASP3 (0.59) | LCKMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL15437849 | 0.77 | MAPT (0.53) | LCKMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL15437771 | 0.74 | PARK7 (0.50) | ALDH1A1DAOTAAR1 | |
| SCHEMBL14302833 | 0.74 | TERT (0.50) | MEN1KMT2AALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL29644739 | 0.73 | LCK (0.57) | LCKMEN1KMT2AACHEL3MBTL1 | |
| SCHEMBL10159032 | 0.72 | KMT2A (0.60) | MEN1KMT2AALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL14560460 | 0.72 | NR1H2 (0.51) | LCKMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL5389994 | 0.71 | LCK (0.68) | LCKCYP1A2CYP2D6CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | claimed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | claimed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | claimed |
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | SOST, MYD88, MSR1 | LCK 3433/4885MEN1 325/4885KMT2A 2720/4885 |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | SOST, MYD88, MSR1 | LCK 3676/4885MEN1 508/4885KMT2A 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.